425 related articles for article (PubMed ID: 20021639)
1. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
2. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
3. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T
Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
[TBL] [Abstract][Full Text] [Related]
4. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
Okishiro M; Kim SJ; Tsunashima R; Nakayama T; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
[TBL] [Abstract][Full Text] [Related]
5. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
[TBL] [Abstract][Full Text] [Related]
6. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
Schmidt MK; Reincke S; Broeks A; Braaf LM; Hogervorst FB; Tollenaar RA; Johnson N; Fletcher O; Peto J; Tommiska J; Blomqvist C; Nevanlinna HA; Healey CS; Dunning AM; Pharoah PD; Easton DF; Dörk T; Van't Veer LJ;
Cancer Res; 2007 Oct; 67(19):9584-90. PubMed ID: 17909070
[TBL] [Abstract][Full Text] [Related]
7. Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.
Koh WP; Van Den Berg D; Jin A; Wang R; Yuan JM; Yu MC
Breast Cancer Res Treat; 2011 Dec; 130(3):1011-9. PubMed ID: 21833626
[TBL] [Abstract][Full Text] [Related]
8. Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.
Jamshidi M; Schmidt MK; Dörk T; Garcia-Closas M; Heikkinen T; Cornelissen S; van den Broek AJ; Schürmann P; Meyer A; Park-Simon TW; Figueroa J; Sherman M; Lissowska J; Keong GT; Irwanto A; Laakso M; Hautaniemi S; Aittomäki K; Blomqvist C; Liu J; Nevanlinna H
Int J Cancer; 2013 May; 132(9):2044-55. PubMed ID: 23034890
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
11. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
[TBL] [Abstract][Full Text] [Related]
12. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
13. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
Fang S; Krahe R; Lozano G; Han Y; Chen W; Post SM; Zhang B; Wilson CD; Bachinski LL; Strong LC; Amos CI
PLoS One; 2010 May; 5(5):e10813. PubMed ID: 20520810
[TBL] [Abstract][Full Text] [Related]
14. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.
Wu CC; Krahe R; Lozano G; Zhang B; Wilson CD; Jo EJ; Amos CI; Shete S; Strong LC
Hum Genet; 2011 Jun; 129(6):663-73. PubMed ID: 21305319
[TBL] [Abstract][Full Text] [Related]
15. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
17. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
[TBL] [Abstract][Full Text] [Related]
18. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.
Ohnstad HO; Castro R; Sun J; Heintz KM; Vassilev LT; Bjerkehagen B; Kresse SH; Meza-Zepeda LA; Myklebost O
Cancer; 2013 Mar; 119(5):1013-22. PubMed ID: 23165797
[TBL] [Abstract][Full Text] [Related]
19. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
20. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]